Why the Mayne Pharma Group Ltd share price is rising today

Shares in pharmaceutical company Mayne Pharma Group Ltd (ASX:MYX) are up 3.15% following an overnight announcement by rival firm Teva Pharmaceutical Industries that has seen a bounce in generic drug manufacturers.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in pharmaceutical company Mayne Pharma Group Ltd (ASX: MYX) are up 3.15% in today's session to 65.5 cents following an overnight announcement by rival firm Teva Pharmaceutical Industries that has seen a bounce in generic drug manufacturers.

Teva announced a restructuring plan where it plans to cut 14,000 jobs (25% of its workforce) and suspend dividends on its ordinary shares. The announcement saw the price of Teva shares surge 10.19% on the day.

At its AGM in late November, Mayne issued a disappointing trading update which confirmed the market's fears prompting a sell off to a 52-week low of 59 cents.

Management noted that the generic drugs sector continues to suffer from deflation driven by the consolidation of buying groups and aggressive competition within the generics market. As a result, group revenue to the end of October was down 12% to $151 million compared to the prior corresponding period. The Generics Product Division is the largest division within the company and saw its sales decline 10% to US$88 million on the prior corresponding period.

Foolish takeaway 

The company does have an intriguing pipeline of future generic products. In FY18, Mayne expects to receive FDA approval for 6 products that will target markets with sales of $US500 million and in FY19, the company expects an even stronger generic pipeline with approximately 8 potential launches that will target markets with sales of $US2 billion.

Mayne does have a lot of potential and is positioned for the ageing population, increasing rate of chronic disease, and rising demand for generics to lower healthcare costs.

Short interest in the stock has declined over the last 2 weeks but remains high at 7.83%. It is probably a bit premature to call a bottom as the generics price deflation cycle may not yet be over.

It is definitely a company Australian investors should keep an eye on for when the the industry returns to more normalised trading conditions. In the meantime, investors might want to look at CSL Limited (ASX: CSL) and Resmed Inc. (CHESS) (ASX:RMD) for exposure to the healthcare sector.

Motley Fool Contributor Tim Katavic has no financial interest in any company mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »